<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256905</url>
  </required_header>
  <id_info>
    <org_study_id>09-0189</org_study_id>
    <nct_id>NCT01256905</nct_id>
  </id_info>
  <brief_title>Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies</brief_title>
  <acronym>Armodafinil</acronym>
  <official_title>Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time&#xD;
      sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in&#xD;
      the attention commonly reported by patients with more advanced Parkinson's disease (PD) and&#xD;
      Lewy body disease (LBD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aims of this study are:&#xD;
&#xD;
      1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia&#xD;
      thalamocortical network, measured through the Electroencephalography (EEG) frequency&#xD;
      analysis, are ameliorated by armodafinil.&#xD;
&#xD;
      Our main hypothesis is that armodafinil can restore the attention and improve cognitive&#xD;
      disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI departure from institution&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">August 8, 2011</completion_date>
  <primary_completion_date type="Actual">August 8, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks)</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinsons Disease</condition>
  <condition>Lewy Bodies Disease</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Armodafinil 150 mg</description>
    <arm_group_label>Armodafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established criteria for diagnosis of PDD (Parkinsons Disease) {Emre M et al. Mov&#xD;
             Disord 2007;22:1689-707} and DLB (Lewy Bodies Disease) {McKeith et al. Neurology&#xD;
             2005;65:1863-72}&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) score between &lt;24; and/or Dementia Rating&#xD;
&#xD;
          -  Scale-2 (DRS-2) score &lt;134;&#xD;
&#xD;
          -  Clinical Assessment of Fluctuation (CAF)&gt;4;&#xD;
&#xD;
          -  Stable anti-parkinsonian medication in the 4 weeks preceding the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cognitive enhancers (Donepezil, Rivastigmine, Galantamine, Modafinil,&#xD;
             Memantine) in the last 4 weeks:&#xD;
&#xD;
        Concomitant use of any medication contraindicated with modafinil/armodafinil; History of&#xD;
        alcohol and substances abuse. Use of medications known to alter the normal EEG activity in&#xD;
        humans during the study period (i.e. clonazepam) History of psychiatric disorders, other&#xD;
        than depression and psychiatric complication of PDD and DLB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Varanese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Parkinsons and Movement Disorders Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Parkinsons and Movement Disorders Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://parkinson.med.nyu.edu/</url>
    <description>armodafinil</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

